Tenax Therapeutics Insider Buys 3,000 Options as CEO Signals Optimism Ahead of Phase‑3 Results

Insider Buying at Tenax Therapeutics Signals Confidence Amid Volatility On January 9, 2026, owner PROEHL GERALD T made a modest purchase of 3,000 stock‑option shares at an intraday price of $15.05, a fraction above the close of $14.70 the previous day. The trade, filed under Form 4, is part of a long history of option activity that began with a single option in 2019 and has steadily increased to 80,000 options bought in July 2025. The current purchase reflects a continuation of that trend, suggesting the owner remains optimistic about the company’s Phase 3 LEVEL study, which is poised to deliver the first topline data on levosimendan for PH‑HFpEF patients.

Implications for Investors and Market Sentiment Tenax’s stock is trading near its 52‑week high, yet its price‑to‑earnings ratio of –11.59 and negative earnings signal that the market is still skeptical about profitability. The insider activity, however, may temper that skepticism. A sizable option purchase at a price slightly above the market can be interpreted as a long bet on upside potential, especially when combined with the company’s recent positive technical signals—a narrowing Bollinger Band and a bearish Marubozu on the 15‑minute chart that investors often view as a potential reversal cue. For investors, the trade adds a layer of insider confidence that may support a rally, but the stock’s volatility and earnings uncertainty mean that caution is still warranted.

What This Means for Tenax’s Future The steady accumulation of options by PROEHL GERALD T indicates a belief that the upcoming topline data will materially improve the company’s valuation. If the Phase 3 results are positive, the company could see a surge in demand for its levosimendan‑based therapy, potentially driving a significant share price increase. Conversely, if results are muted, the existing option positions could become dilutive, increasing the number of shares outstanding once exercised. Thus, the insider activity serves as both a bullish signal and a reminder that Tenax’s future performance remains contingent on clinical outcomes.

Profile of PROEHL GERALD T: A Long‑Term Investor PROEHL GERALD T has maintained a consistent pattern of accumulating stock options over seven years, starting with a single option in 2019 and scaling to large positions of 80,000 and 100,000 options in recent filings. His holdings are almost exclusively in options rather than common shares, suggesting a strategy that balances exposure with limited initial capital outlay. The owner’s most recent purchases—30,000 options in January 2026 and 80,000 options in July 2025—show a willingness to commit significant capital ahead of anticipated catalyst events. Historically, he has not yet exercised any options, indicating a patient, long‑term view that aligns with Tenax’s developmental timeline.

Bottom Line for Investors Insider buying by a seasoned holder like PROEHL GERALD T, coupled with the company’s looming clinical data release, injects a modest amount of bullish sentiment into an otherwise volatile security. While the stock’s fundamental metrics remain weak, the insider activity signals confidence that could catalyze a short‑term price rally if the Phase 3 results validate Tenax’s therapeutic approach. Investors should weigh this insider enthusiasm against the company’s earnings risk and consider a position that limits exposure to the potential downside if clinical outcomes fall short.